This was the stock's second consecutive day of losses.

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...